Get Metropolis Healthcare with full year of free testing at just ₹4999
Need help? Talk to our expert.
WhatsApp
NextGen BRCA Somatic, FFPE tissue
₹ 22,000
NextGen BRCA Somatic, FFPE tissue
₹ 22,000
Booked 51+ booked in last 3 days

NextGen BRCA Somatic, FFPE tissue

Also Known As :

Report
Report 16th day
Fasting
Fasting no
Recommended for
Recommended for Male, Female
NextGen BRCA Somatic Mutation Analysis, FFPE Tissue
₹ 22,000

Next-generation sequencing (NextGen) of BRCA somatic mutations in formalin-fixed paraffin-embedded (FFPE) tissue samples plays a pivotal role in identifying specific genetic alterations within the BRCA genes. This molecular analysis is particularly relevant in the context of PARP inhibitor therapy. PARP inhibitors are a class of targeted cancer treatments that show effectiveness in patients with BRCA mutations, as these mutations impair DNA repair mechanisms. By assessing somatic mutations in the BRCA genes using NextGen sequencing on FFPE tissue samples, healthcare providers can identify actionable genetic changes that inform the use of PARP inhibitor therapies. This personalized approach enhances treatment decisions and potentially improves outcomes for individuals with cancers linked to BRCA mutations.

Frequently asked questions

Find quick answers to the most common questions about health tests, bookings, and reports.

This test measures specific genetic mutations in the BRCA genes. Mutations in these genes increase the risk of developing certain types of cancer, particularly breast and ovarian cancer.

• To identify mutations in the BRCA genes that may increase the risk of developing certain types of cancer

• To determine eligibility for targeted therapies, such as PARP inhibitor therapy

• To assess the response to treatment in patients receiving PARP inhibitor therapy

• To provide a personalised risk assessment for individuals with a family history of breast or ovarian cancer

This test is recommended for individuals who

  •  have a personal or family history of breast or ovarian cancer,
  •  have already been diagnosed with breast or ovarian cancer and want to determine if they have an inherited mutation,
  • are considering or undergoing targeted therapies, such as PARP inhibitor therapy, or
  • have a family member with a known BRCA mutation.

Abnormal results may indicate the presence of specific genetic mutations that increase the risk of developing certain types of cancer.

Book a Home Visit Now

Book any blood test or health checkup and get tested at the comfort of your home.

Why Metropolis Healthcare?

Metropolis has been present for over 43 years in the market.

Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.

NABL & CAP

Accredited labs

Advanced Labs

210+

Advanced Labs

Trusted by

750+ Cities

Global Presence

Scientific Officers

2,000+

Scientific Officers

Proficiency Testing

4,100+

Test & Profiles

Latest Blogs & News

Stay informed with our expert insights and updates.

About Us

Metropolis Healthcare is a leading diagnostic service provider in India. We are a team of dedicated professionals committed to ensuring you and your family receive the most accurate and timely healthcare solutions. We believe in making health care accessible, affordable and evidence-based. Our expert panel are equipped with the latest technology and manned by a certified team of over 4000+ technicians.

In diagnostic services, we have more than three decades of experience servicing diverse stakeholders health advantage packages for men, women and seniors, genetic fitness & corporation in over 650+ tests like Oncology, Neurology, Gynaecology, Haematology, and many more. Our diagnostic services are located in leading doctors and clinics and serve over 15+ cities in India.

Do you have any queries? Or call us now at 0804-8911-400

Proceed
0 items
0
Go to Cart